Home > Boards > US Listed > Biotechs > Opko Health Inc (OPK)

Barrington Stick to Their Buy Rating for Opko

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
JDUB Member Profile
 
Followed By 43
Posts 8,721
Boards Moderated 1
Alias Born 12/07/03
160x600 placeholder
Sian Capital Sends Letter to OPKO Health Regarding its Decision to Apparently Withhold Rayaldee From Many Patients Amidst COV... GlobeNewswire Inc. - 11/20/2020 4:45:00 PM
Sian Capital Issues Open Letter to Stockholders of OPKO Health GlobeNewswire Inc. - 11/12/2020 6:30:00 PM
OPKO Health to Participate in Three Upcoming Investment Conferences GlobeNewswire Inc. - 11/11/2020 9:10:51 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/2/2020 6:57:26 AM
Sian Capital Highlights Paths to Meaningful Value Creation at OPKO Health GlobeNewswire Inc. - 10/29/2020 5:20:36 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 10/29/2020 4:26:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/29/2020 4:08:24 PM
OPKO Health Reports 2020 Third Quarter Business Highlights and Financial Results GlobeNewswire Inc. - 10/29/2020 4:05:10 PM
OPKO Health's BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test PR Newswire (US) - 10/20/2020 8:00:00 AM
OPKO Health to Report Third Quarter 2020 Financial Results on October 29, 2020 GlobeNewswire Inc. - 10/13/2020 12:50:49 PM
OPKO Health's BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools PR Newswire (US) - 10/9/2020 8:00:00 AM
Notice of Class Action Settlement Involving Purchasers of OPKO Health, Inc. Common Stock during the period of September 26, 2... PR Newswire (US) - 10/8/2020 9:08:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/15/2020 10:32:13 AM
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients GlobeNewswire Inc. - 9/15/2020 7:00:10 AM
TNS New Potential Home Run Report Available Now InvestorsHub NewsWire - 9/3/2020 8:35:00 AM
OPKO Health to Participate in Two September Investment Conferences GlobeNewswire Inc. - 9/2/2020 4:05:10 PM
OPKO Health's BioReference Laboratories Announces New York City Schools COVID-19 Testing Program PR Newswire (US) - 9/2/2020 8:00:00 AM
OPKO Health's BioReference Laboratories Launches Best-in-Class Next-Generation Sequencing (NGS) Assay PR Newswire (US) - 9/1/2020 3:55:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/27/2020 8:41:29 AM
OPKO Health's GeneDx Enters into Agreement with Pediatrix Medical Group to Offer Neonatal Genomic Services PR Newswire (US) - 8/12/2020 9:15:00 AM
OPKO Health's GeneDx Adds GenomeXpress to Its Industry-Leading Clinical Genomics Portfolio PR Newswire (US) - 8/6/2020 8:00:00 AM
OPKO Health to Participate in BTIG Virtual Biotechnology Conference GlobeNewswire Inc. - 8/5/2020 3:35:52 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/31/2020 8:54:32 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2020 6:28:10 AM
OPKO Health Reports 2020 Second Quarter Business Highlights and Financial Results GlobeNewswire Inc. - 7/30/2020 4:05:10 PM
JDUB   Wednesday, 09/16/20 03:00:32 AM
Re: None
Post # of 13870 
Barrington Stick to Their Buy Rating for Opko Health Inc
8 hours ago (Sep 15, 2020 05:45PM ET)


Barrington analyst Michael Petusky maintained a Buy rating on Opko Health (NASDAQ:OPK) Inc on Tuesday, setting a price target of $7, which is approximately 120.82% above the present share price of $3.17.

Petusky expects Opko Health Inc to post earnings per share (EPS) of $0.05 for the third quarter of 2020.

The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Opko Health, with an average price target of $8.
The analysts price targets range from a high of $10 to a low of $6.5.

In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $301.21 million and a net profit of $28.29 million. The company's market cap is $2.12 billion.

According to TipRanks.com, Barrington analyst Michael Petusky is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 4.0% and a 48.62% success rate.

OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Barrington Stick to Their Buy Rating for Opko Health Inc

Add a Comment

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences